474 completed, 246 unknown, 230 recruiting, 139 terminated. 616 Phase 2, 263 Phase 1, 164 Not applicable, 146 Phase 3, 15 Early Phase 1.
Follow Neoplasms, Squamous Cell: new trials by email Literature Review of Neoplasms, Squamous Cell trials Research Report on Neoplasms, Squamous Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma Induction radiotherapy, Vilastobart, Opdualag - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 26 | 2027-02-01 | 2026-10-27 |
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions TROP2 CAR/IL-15 TGFBR2 KO NK cells - Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2026-12-31 | 2026-11-03 |
| A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection SYS6010, SG001, SG001 placebo-mimicking - Esophageal Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 585 | 2026-12-30 | 2026-11-09 |
| Screening Psychosocial Distress in Head and Neck Cancer Psychosocial distress screening using the Distress Thermometer - Head and Neck Cancer (H&N) | Not yet recruiting | Hôpital NOVO | 80 | 2026-11-30 | 2026-10-01 | |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures Panitumumab-IRDye800 - Cancer, Chemotherapy | Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 6 | 2026-11-01 | 2026-11-05 |
| Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma Standardized Management Protocol for Esophageal Fistula - Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Fistula | Not yet recruiting | Peking University Cancer Hospital & Institute | 32 | 2026-11-01 | 2026-11-05 | |
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer | Phase 2 | Not yet recruiting | GOG Foundation | 28 | 2026-11-01 | 2026-11-09 |
| Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) Nivolumab-IRDye800 - HNSCC, SCC - Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 18 | 2026-10-30 | 2026-11-12 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia Metformin, Naproxen Sodium - Fanconi Anemia, Head and Neck Cancer | Phase 1 | Recruiting | Rockefeller University | 80 | 2026-10-14 | 2026-10-28 |
| Basal Cell Carcinoma Chemoprevention Trial 5% Imiquimod cream, Placebo Vehicle Control Cream - Basal Cell Carcinoma | Phase 3 | Recruiting | VA Office of Research and Development | 1630 | 2026-10-06 | 2026-11-02 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma Panitumumab-IRDye800, [18F]NOTA-ABY-030 - HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-10-01 | 2026-10-19 |
| Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-10-01 | 2026-09-16 | |
| Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 33 | 2026-10-01 | 2026-09-16 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
Showing 20 of 1323. Sign in to see all of them.
Carcinoma, Squamous Cell (628) · Esophageal Squamous Cell Carcinoma (626) · Head and Neck Neoplasms (206) · Squamous Cell Carcinoma of Head and Neck (200) · Esophageal Neoplasms (187) · Carcinoma, Non-Small-Cell Lung (109) · Adenocarcinoma Of Esophagus (98) · Carcinoma, Basal Cell (88) · Melanoma (84) · Skin Neoplasms (68) · Neoplasms (65) · Adenocarcinoma (56) · Neoplasm Metastasis (53) · Colorectal Neoplasms (49)
Neoplasms by Histologic Type (1317) · Neoplasms, Glandular and Epithelial (1315) · Neoplasms (1258) · Carcinoma (1230) · Neoplasms by Site (1113) · Head and Neck Neoplasms (763) · Digestive System Diseases (712) · Gastrointestinal Diseases (706) · Digestive System Neoplasms (704) · Gastrointestinal Neoplasms (694) · Esophageal Diseases (655) · Carcinoma, Squamous Cell (636) · Esophageal Neoplasms (475) · Skin and Connective Tissue Diseases (179)
Cisplatin (201) · Radiotherapy (132) · Paclitaxel (111) · Fluorouracil (88) · pembrolizumab (82) · Carboplatin (80) · Cetuximab (60) · Docetaxel (58) · Drug Therapy (53) · Nivolumab (37) · Radiotherapy, Intensity-Modulated (36) · Irinotecan (33) · Radiation (33) · tislelizumab (31) · 130-nm albumin-bound paclitaxel (29)
Fudan University (36) · Sun Yat-sen University (31) · Memorial Sloan Kettering Cancer Center (28) · M.D. Anderson Cancer Center (21) · Tianjin Medical University Cancer Institute and Hospital (18) · National Cancer Institute (NCI) (17) · Peking University (17) · The First Affiliated Hospital of Zhengzhou University (14) · UNC Lineberger Comprehensive Cancer Center (14) · Merck Sharp & Dohme LLC (13) · Alpha Tau Medical LTD. (12) · Shanghai Chest Hospital (12) · Hebei Medical University Fourth Hospital (11) · National Taiwan University Hospital (11) · H. Lee Moffitt Cancer Center and Research Institute (10)
United States (500) · China (400) · France (113) · United Kingdom (73) · South Korea (67) · Spain (66) · Taiwan (65) · Canada (62) · Italy (58) · Belgium (55) · Germany (55) · Australia (41) · Japan (41) · Netherlands (36) · Israel (28)
David H. Ilson, MD, PhD (8) · Hui Liu, Professor (5) · Lin Shen, MD (5) · K Mosterd, MD, PhD (4) · Mian Xi, MD (4) · Shegan Gao, Doctor (4) · Tanyou Shan, Master (4) · Thomas Ruhstaller, MD (4) · Xiaozhi Yuan, Master (4) · Andrew Sikora, MD, PhD (3)
PMID 36990609, PMID 26254683, PMID 30089078, PMID 33373868, PMID 41309527, PMID 18309943, PMID 19465425, PMID 21684205, PMID 24982463, PMID 25057165, PMID 26808342, PMID 28742685, PMID 32017652, PMID 33538338, PMID 34160577, PMID 34454674, PMID 35440464, PMID 38710003, PMID 40373876, PMID 40467307, PMID 41531940, PMID 42580817, PMID 11208820, PMID 11391598, PMID 11870157, PMID 12049861, PMID 12167786, PMID 12771885, PMID 12885811, PMID 14673047, PMID 14759776, PMID 15061852, PMID 15151953, PMID 15533252, PMID 15753371, PMID 15800321, PMID 16129366, PMID 16235286, PMID 16467544, PMID 16515704, PMID 16601427, PMID 17259930, PMID 17327856, PMID 17921712, PMID 17960012, PMID 17960013, PMID 18270704, PMID 18474878, PMID 18574157, PMID 18640307
2019 (11), 2023 (9), 2017 (7), 2014 (6), 2015 (4), 2016 (4), 2018 (4), 2008 (3), P30CA043703 (3), U10CA032102 (3), 2009 (2), 2025 (2), P01CA021239 (2), P30CA006927 (2), P30CA008748 (2)